CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo®, Inc. (NSYE MKT: MYO), a commercial stage medical robotics company, today announced the expansion of its management team with three new full-time positions in medical affairs, sales and marketing. The expansion marks the company’s accelerated commercialization of its MyoPro line of powered orthoses after raising growth capital through its IPO in June 2017.
Dr. Brandon Green, DO, BOCP, has assumed a full-time role as Myomo’s Chief Medical Officer. In this position, Dr. Green conducts clinical presentations and training for physicians and other clinicians involved with fitting MyoPro on their patients. Additionally, he engages with private and government payers on reimbursement policies for the MyoPro product line and participates in the design and review of clinical studies of MyoPro in conjunction with the company’s Scientific Advisory Board. Dr. Green is a licensed physician, with training in general surgery and rehab medicine, and a certified prosthetist specializing in upper extremity prosthetic restoration.
Lorraine Hale has joined Myomo as the National Business Development Manager. Hale oversees the company business and enterprise development with medical clinicians, the Veterans Health Administration and orthotic and prosthetic providers. Her mission is to support the sales team in their efforts to increase the clinical adoption of MyoPro across the country. Hale brings extensive sales and management experience with medical devices and previously worked at Touch Bionics (now part of Ossur), a leader in upper limb prosthetics technology.
Cliff Conneighton has assumed a full-time position as Myomo’s Chief Marketing Officer, responsible for the company’s marketing strategy and programs. In this role, Conneighton raises awareness of MyoPro among potential patients and clinicians and develops marketing programs in support of the company’s network of Centers of Excellence. Conneighton oversees all of the company’s advertising, public relations and social media activity, in addition to product management of the MyoPro line. Conneighton brings to Myomo extensive experience in scaling businesses, having served as chief marketing officer for four technology companies, including three that were acquired by Fortune 100 or Global 200 companies.
“The proceeds raised from our IPO have positioned us to grow our operations,” said Paul R. Gudonis, Chairman and CEO of Myomo. “We’re pleased to add three experienced and dynamic professionals to our management team to help us expand our reach, increase our sales and marketing efforts and bring MyoPro to more individuals in the U.S. and internationally.”
Myomo plans to add field sales and clinical staff in regional locations across the U.S. as the company seeks to establish additional Centers of Excellence in other metro markets. Additionally, Myomo is preparing to launch MyoPro in Germany in partnership with Ottobock, a major provider of orthotics and prosthetics technology worldwide.
Myomo, Inc. is a commercial stage medical robotics Company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT and the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, and the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Other risks and uncertainties include, among others, risks related to the Company’s liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.